---
title: "High‑alert medicines in Sri Lanka: list development and pilot error‑prevention strategies"
id: "medrxiv-7-development-of-a-high-alert-medicines-list-and-pilot-testing-of-error"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-7-development-of-a-high-alert-medicines-list-and-pilot-testing-of-error"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1"
published_at: "2026-08-26T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# High‑alert medicines in Sri Lanka: list development and pilot error‑prevention strategies
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-7-development-of-a-high-alert-medicines-list-and-pilot-testing-of-error
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1)
- **Published At:** 2026-08-26T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This mixed‑methods cross‑sectional study developed **high‑alert medication** lists and piloted error prevention strategies for Sri Lankan hospitals and community settings. - Initial data collection used an interviewer‑administered questionnaire with n=315 respondents to identify candidate medicines and practices. - Five stakeholder consultative meetings involving multidisciplinary clinicians (n=62) were convened to reach consensus on the lists. - Subsequent testing included an additional interviewer‑administered questionnaire (n=45) and three semi‑structured focus group discussions (total n=45) to explore implementation barriers. - The process resulted in identification of **100 medicines** as high‑alert for acute care settings and **40 medicines** for community settings; the full lists are provided as S1 and S2 appendices. - Ethical approvals were obtained from the Ethics Review Committee, Faculty of Medicine, University of Colombo (Ref: 18‑008), the National Hospital of Sri Lanka (Ref: AAj/ETH/COM/2017) and Colombo South Teaching Hospital (Ref: PL/MO/2018‑2019); approvals were renewed annually and covered the full data collection period. - Permissions to photograph hospital pharmacies and written informed consent were obtained; no patient‑identifiable information is shown and participation was voluntary. - The anonymized survey dataset is available from the corresponding author on reasonable request; all relevant data are within the manuscript and supporting files. - The authors declared no competing interests and followed applicable reporting guidelines; trial registration statements and other procedural declarations were included in the submission. - The study addresses an identified gap: previously there was no formal high‑alert medicine list or error prevention strategy for Sri Lankan hospitals, and this work provides both lists and pilot implementation insights for local practice.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=DXODrreSNccaIz1N4jyPXntTgfKH.NxGQQN0avYUA7s-1787779524.595299-1.2.1.1-orKl1tCK7EV95QpC1Ikxsns72tgxvaqfzLBgw2wMTi05rF1EjuQFEG9aKE1uQ3u8) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Development of a high-alert medicines list and pilot testing of error prevention strategies in Sri Lanka: a cross-sectional mixed methods study [ View ORCID Profile](http://orcid.org/0009-0007-4774-6933)Wasana Sudarshi Kumari Bandara, Priyadarshani Galappatthy, Nithushi Rajika Samaranayake, Dewani - Ranaweera doi: https://doi.org/10.64898/2026.08.24.26361195 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Wasana Sudarshi Kumari Bandara 1 Colombo South Teaching Hospital; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Wasana%2B%2BSudarshi%2BKumari%2BBandara%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bandara%20W&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AWasana%2B%2BSudarshi%2BKumari%2BBandara%2B) * [ORCID record for Wasana Sudarshi Kumari Bandara](http://orcid.org/0009-0007-4774-6933 "Open in new tab") * For correspondence: wasanasbandara@gmail.com Priyadarshani Galappatthy 2 University of Colombo Faculty of Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Priyadarshani%2BGalappatthy%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Galappatthy%20P&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APriyadarshani%2BGalappatthy%2B) Nithushi Rajika Samaranayake 3 University of Sri Jayewardenepura Faculty of Medical Sciences; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Nithushi%2B%2BRajika%2BSamaranayake%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Samaranayake%20N&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ANithushi%2B%2BRajika%2BSamaranayake%2B) Dewani - Ranaweera 4 Ministry of Health: Government of Sri Lanka Ministry of Health Sri Lanka * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dewani%2B%2B-%2BRanaweera%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Ranaweera%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADewani%2B%2B-%2BRanaweera%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1286710/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1286710/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1286710/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1286710/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1286710/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract High-alert medications are a leading cause of preventable patient harm worldwide, but there was no any high alert medicine list or error prevention strategy for Sri Lankan hospitals. This study addresses that gap by using interviewer administered questionnaire [n=315], five stakeholder consultative meetings [n=62] including multidisciplinary clinicians to reach consensus, followed by interviewer administered questionnaire [n=45], semi-structured three focus group discussions [n=45] to explore implementation barriers. Our findings identified [n=100] medicines as high-alert for acute care settings, and [n=40] medicines for community settings. I believe this article will be of interest and benefit to the readers of your journal. I declare that this manuscript is original, has not been published before and is not currently being considered for publication elsewhere.No conflicts of interest exist. Ethical approval was obtained from the Ethics Review Committee of Faculty of Medicine, University of Colombo (Reference number: 18-008) and approval were renewed annually as required and Ethical Review Committees of National Hospital of Sri Lanka (Reference number: AAj/ETH/COM/2017) and Colombo South Teaching Hospital (Reference number: PL/MO/2018-2019).All approval covered the full data collection period. Permission to photograph hospital pharmacies were obtained from chief pharmacist of participating hospital and no patient-identifiable information is shown.Written informed consent was obtained from all participants. The high alert medicine lists for acute and community settings are provided as S1 and S2 appendices.As corresponding author, I confirm that the manuscript has been read and approved for submission by all the named authors. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics approval and consent to participate was approved by the Ethics Review Committee of Faculty of Medicine, University of Colombo (Reference number: 18-008) and Ethical Review Committees of National Hospital of Sri Lanka (NHSL) (Reference number: AAj/ETH/COM/2017) and Colombo South Teaching Hospital (CSTH) (Reference number: PL/MO/2018-2019). All approvals were renewed annually and covered the full study period. Permissions from all selected community pharmacies were obtained prior to commencing the study. Participation was voluntary, and informed written and verbal consent were obtained from all participants. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All relevant data are within the manuscript and its Supporting Information files.The anonymized survey dataset is available from the corresponding author upon reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.24.26361219v1 "Joint contributions of metabolic dysfunction and biological aging to cardiometabolic multimorbidity and disease progression: a prospective cohort study")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.24.26357362v1 "Calibrating self-reported BMI in national surveillance: impact on obesity misclassification and socioeconomic inequalities in Portugal") Posted August 26, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/26/2026.08.24.26361195.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.24.26361195v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/26/2026.08.24.26361195.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Development of a high-alert medicines list and pilot testing of error prevention strategies in Sri Lanka: a cross-sectional mixed methods study Wasana Sudarshi Kumari Bandara, Priyadarshani Galappatthy, Nithushi Rajika Samaranayake, Dewani - Ranaweera medRxiv 2026.08.24.26361195; doi: https://doi.org/10.64898/2026.08.24.26361195 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.24.26361195v1%26text%3DDevelopment%2520of%2520a%2520high-alert%2520medicines%2520list%2520and%2520pilot%2520testing%2520of%2520error%2520prevention%2520strategies%2520in%2520Sri%2520Lanka%253A%2520a%2520cross-sectional%2520mixed%2520methods%2520study "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.24.26361195v1%26t%3DDevelopment%2520of%2520a%2520high-alert%2520medicines%2520list%2520and%2520pilot%2520testing%2520of%2520error%2520prevention%2520strategies%2520in%2520Sri%2520Lanka%253A%2520a%2520cross-sectional%2520mixed%2520methods%2520study "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.24.26361195v1%26title%3DDevelopment%2520of%2520a%2520high-alert%2520medicines%2520list%2520and%2520pilot%2520testing%2520of%2520error%2520prevention%2520strategies%2520in%2520Sri%2520Lanka%253A%2520a%2520cross-sectional%2520mixed%2520methods%2520study%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.24.26361195v1%26title%3DDevelopment%2520of%2520a%2520high-alert%2520medicines%2520list%2520and%2520pilot%2520testing%2520of%2520error%2520prevention%2520strategies%2520in%2520Sri%2520Lanka%253A%2520a%2520cross-sectional%2520mixed%2520methods%2520study "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.24.26361195) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.24.26361195v1&count=horizontal&via=&text=Development%20of%20a%20high-alert%20medicines%20list%20and%20pilot%20testing%20of%20error%20prevention%20strategies%20in%20Sri%20Lanka%3A%20a%20cross-sectional%20mixed%20methods%20study&counturl=www.medrxiv.org/content/10.64898/2026.08.24.26361195v1 "Tweet This") ## Subject Area * [Health Policy ](https://www.medrxiv.org/collection/health-policy) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (612) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (892) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (325) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4752) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (473) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (406) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (639) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1610) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15792) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6961) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (725) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1050) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4957) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1422) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1730) * [Hematology](https://www.medrxiv.org/collection/hematology) (577) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1328) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16226) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1157) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (661) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (717) * [Neurology](https://www.medrxiv.org/collection/neurology) (7156) * [Nursing](https://www.medrxiv.org/collection/nursing) (360) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1071) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1223) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (998) * [Oncology](https://www.medrxiv.org/collection/oncology) (3561) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1032) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (390) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (444) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (464) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1769) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (730) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (758) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5809) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9661) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2371) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1426) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1236) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (631) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (762) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (571) * [Surgery](https://www.medrxiv.org/collection/surgery) (760) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (106) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (301) * [Urology](https://www.medrxiv.org/collection/urology) (285) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to preprints they are evaluating. Reviews are posted with the consent of the authors. TRiP reviews are part of a peer review pilot project in which particip
## Related Clinical Research

- [Most-favored nation pharma deals target Medicaid but exempt Medicare, analysts say](https://medichelpline.com/clinical-feed/stat-news-0-stat-how-trump-s-latest-pharma-deals-may-undermine-efforts-to-rein-in-drug-costs.md)
- [Immune checkpoints in metabolic diseases and cancer: mechanisms and therapeutic potential](https://medichelpline.com/clinical-feed/pubmed-42680727.md) (DOI: 10.1038/s41392-026-02810-5)
- [Analysis: Five key questions about Trump’s latest drugmaker deals and what's still unknown](https://medichelpline.com/clinical-feed/stat-news-0-stat-5-burning-questions-on-trump-s-latest-deals-with-drugmakers.md)
- [Depression and Long-Term HbA1c Variability Linked to Higher Cardiovascular‑Renal Risk in Type 2 Di](https://medichelpline.com/clinical-feed/pubmed-42671118.md) (DOI: 10.1002/dmrr.70222)
- [Pharma Friday: FDA OKs Rasonque for Metastatic Pancreatic Cancer and Mounjaro CV Approval — Sept 4](https://medichelpline.com/clinical-feed/endocrine-news-0-pharma-friday-september-4-2026.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.